Real world experience with axitinib (Inlyta)

This paper, published in the online Practice Update journal Renal Cell Carcinoma this week, provides real world efficacy data for axitinib (Inlyta) in second-line treatment and beyond for metastatic renal cell carcinoma. The article suggests that the real world efficacy data for axitinib is similar to that seen in clinical trials, with a median overall […]

read more

First-line avelumab plus axitinib combination shows promising efficacy in advanced kidney cancer

Results from an early phase Ib clinical trial of avelumab plus axitinib combination for the first-line treatment of advanced renal cell carcinoma (RCC) were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago yesterday. Fifty-five people with advanced RCC who had not received any previous treatment (treatment-naïve patients) were recruited into […]

read more

Immunotherapy combined with VEGF inhibitors for kidney cancer

In this video interview, Dr Shilpa Gupta, assistant professor, Haematology, Oncology and Transplantation Division, University of Minnesota, USA, discusses combining VEGF inhibitors with immunotherapy for patients with kidney cancer. Since kidney cancer is a VEGF-driven disease, it makes sense to combine VEGF inhibitors, such as sunitinib or axitinib, with immunotherapy drugs, such as nivolumab or […]

read more

Dalantercept plus axitinib combination may improve outcomes for people with advanced kidney cancer

Results from the first part of the phase 2 DART study have been released showing that a combination of dalantercept with axitinib treatment may improve the clinical outcomes of people with advanced renal cell carcinoma (RCC) who have been previously treated. Axitinib is a tyrosine kinase inhibitor (TKI) that targets vascular endothelial growth factor (VEGF) to […]

read more

Tracon Pharmaceuticals present results from phase 1b trial of TCR105 plus axitinib in kidney cancer

TRACON Pharmaceuticals presented final results from a phase 1b clinical trial combining TRC105 with Inlyta® (axitinib) in patients with advanced or metastatic renal cell carcinoma (RCC) at the European Society for Medical Oncology (ESMO) Congress in Copenhagen, Denmark, earlier this week. This study was an open-label, dose escalation and expansion phase 1b study, which enrolled a total […]

read more
Showing 61 to 65 of 65 results